drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
The main use of BCG is for vaccination against tuberculosis. BCG vaccine can be administered after birth intradermally. BCG vaccination can cause a false positive Mantoux test. The most controversial aspect of BCG is the variable efficacy found in different clinical trials, which appears to depend on geography. Trials in the UK consistently show a 60 to 80% protective effect. Still, those trials conducted elsewhere have shown no protective effect, and efficacy appears to fall the closer one gets to the equator. A 1994 systematic review found that BCG reduces the risk of getting tuberculosis by about 50%. Differences in effectiveness depend on region, due to factors such as genetic differences in the populations, changes in environment, exposure to other bacterial infections, and conditions in the laboratory where the vaccine is grown, including genetic differences between the strains being cultured and the choice of growth medium. A systematic review and meta-analysis conducted in 2014 demonstrated that the BCG vaccine reduced infections by 19–27% and reduced progression to active tuberculosis by 71%. The studies included in this review were limited to those that used interferon gamma release assay. The duration of protection of BCG is not clearly known. In those studies showing a protective effect, the data are inconsistent.
== History == Curcumin was named in 1815 when Henri Auguste Vogel and Pierre Joseph Pelletier reported the first isolation of a "yellow coloring-matter" from the rhizomes of turmeric. Later, it was found to be a mixture of resin and turmeric oil. In 1910, Milobedzka and Lampe reported the chemical structure of curcumin to be as diferuloylmethane. Later in 1913, the same group accomplished the synthesis of the compound. Although used in traditional medicine, the possible therapeutic properties of turmeric or curcumin remain undetermined.
==== Brown ==== Human feces ordinarily has a light to dark brown coloration, which results from a combination of bile, and bilirubin derivatives of stercobilin and urobilin, from dead red blood cells. Normally it is semisolid, with a mucus coating.
== Environmental presence == In 2021, dextrorphan was identified in >75% of sludge samples taken from 12 wastewater treatment plants in California. The same study associated dextrorphan with estrogenic activity by using predictive modelling, before observing it in in vitro.
Sources: en.wikipedia.org
==== Modern Inca roads ==== Today, many people travel to South America to hike the Inca trail. Walking and climbing the trail not only serves the purpose of allowing visitors to experience the historic pathways of the Inca people, but it allows for tourists and locals to see the Inca ruins, mountains, and exotic vegetation and animals.
In the 17th century Guillaume Amontons discovered a regular relationship between the pressure and temperature of a gas at constant volume. Some introductory physics textbooks still define the pressure-temperature relationship as Gay-Lussac's law. Gay-Lussac primarily investigated the relationship between volume and temperature and published it in 1802, but his work did cover some comparison between pressure and temperature. Given the relative technology available to both men, Amontons could only work with air as a gas, whereas Gay-Lussac was able to experiment with multiple types of common gases, such as oxygen, nitrogen, and hydrogen.
=== Present day === Modern embalming is most often performed to ensure a better presentation of the deceased for viewing by friends and relatives. It is also used for medical research or training, transportation of deceased, especially across national borders, and in many instances for above ground burial in a vault or mausoleum. A successful viewing of the body is considered to be helpful in the grieving process. Embalming has the potential to prevent mourners from having to deal with the decomposition and eventual putrescence of the body. Despite a common misconception, embalming is not mandatory in the United States, although it is a general legal requirement for international repatriation of human remains to the U.S. (exceptions do occur). There are no universal international preservation requirements for repatriation of human remains, but requirements for embalming do exist for a variety of countries depending on locality and circumstance. Some international standards do exist however, such as the Strasbourg Agreement of the Council of Europe, agreed to by more than 20 States in Europe, which only requires embalming in cases where the individual died due to an infectious disease.
Sources: en.wikipedia.org
Rush's popularity reached its pinnacle with the release of Moving Pictures in February 1981. Essentially, Moving Pictures continued where Permanent Waves left off, extending the trend of accessible and commercially friendly progressive rock which helped thrust them into the spotlight. The lead track, "Tom Sawyer", is probably the band's best-known song. When it was released, it reached No. 24 on the Canadian Top 40 Singles Chart, No. 44 on the Billboard Hot 100, and No. 8 on the new US Album Rock Tracks chart. The second single, "Limelight", also received a strong response from listeners and radio stations, going to No. 18 in Canada, No. 54 on the Hot 100, and No. 4 on the US Album Rock Tracks Chart. Moving Pictures was Rush's last album to feature an extended song, the 11-minute "The Camera Eye". The song contained the band's heaviest usage of synthesizers yet, hinting that Rush's music was shifting direction once more. Moving Pictures became the band's first album to reach No. 1 on the Canadian Albums Chart, and also reached No. 3 on the US Billboard 200 and UK album charts; it has been certified quintuple platinum by both the Recording Industry Association of America and Music Canada. After the success of Moving Pictures, Rush released their second live recording, Exit... Stage Left, in 1981.
A lobotomy (from Greek λοβός (lobos) 'lobe' and τομή (tomē) 'cut, slice') or leucotomy is a discredited form of neurosurgical treatment for psychiatric disorder or neurological disorder (e.g. epilepsy, depression) that involves severing connections in the brain's prefrontal cortex. The surgery severs most of the connections to and from the prefrontal cortex, and the anterior part of the frontal lobes of the brain. From the 1930s until the 1970s, the treatment was used for handling psychiatric disorders as a mainstream procedure in some countries. A preoccupation with the ability to work and personal responsibility over patient well-being were contributing factors to the prevalence of lobotomies in the United States. The originator of the procedure, Portuguese neurologist António Egas Moniz, shared the Nobel Prize for Physiology or Medicine of 1949 for the "discovery of the therapeutic value of leucotomy in certain psychoses", although the awarding of the prize has been subject to controversy. The procedure was modified and championed by Walter Freeman, who performed the first lobotomy at a mental hospital in the United States in 1936. Its use increased dramatically from the early 1940s and into the 1950s; by 1951, almost 20,000 lobotomies had been performed in the US and proportionally more in the United Kingdom. More lobotomies were performed on women than on men: a 1951 study found that nearly 60% of American lobotomy patients were women, and limited data shows that 74% of lobotomies in Ontario from 1948 to 1952 were performed on female patients.
Colombian art has over 3,000 years of history. Colombian artists have captured the country's changing political and cultural backdrop using a range of styles and mediums. There is archeological evidence of ceramics being produced earlier in Colombia than anywhere else in the Americas, dating as early as 3,000 BCE. The earliest examples of gold craftsmanship have been attributed to the Tumaco people of the Pacific coast and date to around 325 BCE. Roughly between 200 BCE and 800 CE, the San Agustín culture, masters of stonecutting, entered its "classical period". They erected raised ceremonial centers, sarcophagi, and large stone monoliths depicting anthropomorphic and zoomorphic forms out of stone. Colombian art has followed the trends of the time, so during the 16th to 18th centuries, Spanish Catholicism had a huge influence on Colombian art, and the popular baroque style was replaced with rococo when the Bourbons ascended to the Spanish crown. During this era, as a Spanish colony, the most important painters were Gregorio Vásquez de Arce y Ceballos, Gaspar de Figueroa, Baltasar Vargas de Figueroa, Baltasar de Figueroa the Elder, Antonio Acero de la Cruz and Joaquín Gutiérrez, of which their works are preserved. Also important was Alonso de Narváez who, although born in the province of Seville, spent most of his life in colonial Colombia, also the Italian Angelino Medoro, lived in Colombia and Peru, and left works of art preserved in several churches in Tunja city.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.